Evidence map›Paper›PMID 35070993›Full record

ArticleFrontiers in oncology2021

Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients.

Ana Gonzalez-Moya, Stéphane Supiot, Valérie Seegers, Thibaut Lizée, Florence Legouté, Tanguy Perennec, Gilles Calais

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ana Gonzalez-MoyaDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, Angers, France.
Stéphane SupiotDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
Valérie SeegersDepartment of Medical Biostatistics, Institut de Cancérologie de l'Ouest, Angers, France.
Thibaut LizéeDepartment of Radiation Oncology, Jean Bernard Center, Inter-Regional Institute of Oncology, Le Mans, France.
Florence LegoutéDepartment of Radiation Oncology, Hospital Center, La Roche sur Yon, France.
Tanguy PerennecDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
Gilles CalaisDepartment of Radiation Oncology, University Hospital Center, Tours, France.
Institut de Cancérologie de l'Ouest · FRCentre Hospitalier Départemental Vendée · FRCentre Hospitalier Universitaire de Tours · FRCentre Jean Bernard · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough salvage and adjuvant radiotherapy (RT) are effective in prostate cancer (PC) patients, 30%-40% of men will have disease progression. The objective was to describe the pattern of recurrence in PC patients with biochemical failure (BF) following postoperative RT.

methodsWe retrospectively analyzed 935 PC patients treated from 2009 to 2019 with adjuvant or salvage RT at the Institut de Cancérologie de l'Ouest. Of these, 205 (22%) developed BF of whom 166 underwent imaging. Patients with identified radiologic failure prior any specific treatment were included to determine the site of relapse categorized as local (L)-only, locoregional (LR), or metastatic (M) recurrence. Main disease characteristics and RT fields were examined in relation to sites of recurrence.

resultsOne hundred forty-one patients were identified with 244 sites of failure on imaging. Of these, 108 patients had received RT to the PB alone and 33 RT to the PB and pelvic lymph nodes (PB+PLN). Androgen-deprivation therapy was used concomitantly in 50 patients (35%). The median PSA at imaging was 1.6 ng/ml (range, 0-86.7). In all, 74 patients (52%) had M disease (44% in the PB group and 79% in the PB+PLN group), 61 (43%) had LR failure (52% in the PB alone group and 15% in the PB+PLN group), and six (4%) had L-only failure, at a median of 26.7 months (range, 5-110.3) from RT. Metastases were in extra-pelvic LN (37 (15%)), bones (66 (27%)), and visceral organs (eight (3%)). Fifty-three (48%) of the pelvic LN failures in the PB group would have been encompassed by standard PLN RT volume.

conclusionWe found that most patients evaluated for BF after postoperative RT recurred outside the RT field. Isolated pelvic nodal failure was rare in those receiving RT to the PB+PLN but accounted for half of failures in those receiving PB alone RT. Imaging directed salvage treatment could be helpful to personalize radiation therapy plan.

Indexed as

adjuvant/salvage radiotherapypattern of recurrencepelvic radiotherapyprostate bed radiotherapyprostate cancer

Identifiers

PMID35070993
PMCPMC8766670
OpenAlexW4206679195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.